key: cord-0886870-x60e4duv
authors: Johnston, M.; Ates, H. C.; Glatz, R. T.; Mohsenin, H.; Schmachtenberg, R.; Göppert, N.; Huzly, D.; Urban, G. A.; Weber, W.; Dincer, C.
title: Multiplexed biosensor for point-of-care COVID-19 monitoring: CRISPR-powered unamplified RNA diagnostics and protein-based therapeutic drug management
date: 2022-04-06
journal: nan
DOI: 10.1101/2022.03.30.22271928
sha: 8f31d1883b8b22acf3deb6dc7cd96f489895bad9
doc_id: 886870
cord_uid: x60e4duv

In late 2019 SARS-CoV-2 rapidly spread to become a global pandemic, therefore, measures to attenuate chains of infection, such as high-throughput screenings and isolation of carriers were taken. Prerequisite for a reasonable and democratic implementation of such measures, however, is the availability of sufficient testing opportunities (beyond reverse transcription PCR, the current gold standard). We, therefore, propose an electrochemical, microfluidic multiplexed biosensor in combination with CRISPR/Cas-powered assays for point-of-care nucleic acid testing. In this study, we simultaneously screen for and identify SARS-CoV-2 infections (Omicron-variant) in clinical specimens (Sample-to-result time: ~30 min), employing LbuCas13a, whilst bypassing reverse transcription as well as target amplification of the viral RNA, both of which are necessary for detection via PCR and multiple other methods. In addition, we demonstrate the feasibility of combining assays based on different classes of biomolecules, in this case protein-based antibiotic detection, on the same device. The programmability of the effector and multiplexing capacity (up to six analytes) of our platform, in combination with a miniaturized measurement setup, including a credit card sized near field communication (NFC) potentiostat and a microperistaltic pump, provide a promising on-site tool for identifying individuals infected with variants of concern and monitoring their disease progression alongside other potential biomarkers or medication clearance.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly infectious member of the SARS-related Betacoronavirus (Sarbecovirus) family that probably emerged from a zoonotic reservoir in December of 2019 1 and has, to date, caused, approximately 412 million confirmed cases and about 5.8 million deaths 2 . Summarized under the name 'COVID-19' it elicits numerous symptoms like dry cough, fever, headaches, pneumonia, diarrhea, anosmia and others 3 that are especially dangerous for the elderly and individuals with comorbidities 4 . Patients experiencing these symptoms, but also asymptomatic individuals (incidence ranging from 17.9 to 39.8% 5, 6 ), whose timeframe of viral shedding can even exceed the symptomatic carrier's 7 , substantially contribute to transmission 4,8-10 via respiratory droplets, fomites, direct or indirect contact 11 . Identification of these individuals via RT-qPCR, however, is difficult since the method is not necessarily suited for high-throughput analysis and difficult to implement in resource-limited environments 12 . Other drawbacks are comparability between labs 13, 14 , an overestimation of infectious virions 15 , and a rather lengthy sample processing time of approximately 4-6 hours.

Hence, in recent years we have witnessed the emergence of a multitude of novel methods for the detection of viral nucleic acids, many of them employing CRISPR-effectors in combination with an amplification strategy for the genetic targets [16] [17] [18] . CRISPR, which is short for clustered regularly interspaced short palindromic repeats, was discovered as a mechanism of adaptive immunity in bacteria against viruses 19 and has since been used in various applications in biotechnology -most prominently gene editing 20 -in association with its effector: CRISPR associated protein 9 (Cas9).

However, cleavage capability of the dual-RNA-guided endonuclease is restricted to double stranded DNA and requires the presence of a protospacer adjacent motif (PAM), located next to the target sequence 21 , which renders the effector unsuitable for the detection of circulating RNAs.

In this study, we extend the CRISPR-Cas-powered assay, that we already established for a signature microRNA (miRNA)-cluster, dysregulated in pediatric medulloblastoma patients 22 onto a novel multiplexed, microfluidic electrochemical biosensing device, for the simultaneous detection of two genetic sequences characteristic for SARS-CoV-2. Instead of using Cas12 (a class 2 effector, targeting single-stranded DNAs and RNAs and upon activation by target recognition collaterally cleaving double stranded DNA 23, 24 ) like Broughton 16 , Ding 25 , or Gong and colleagues 26 , in this study we employ the Leptotrichia buccalis (Lbu)Cas13a effector and thereby bypass the need for a protospacer adjacent motif (PAM) in the target for recognition by the effector. Like for Cas12, target-specificity of LbuCas13a depends on guidance by a CRISPR (cr)-RNA 27 , which can be modified to target any RNA sequence of interest and is therefore perfectly suited to keep pace with spontaneous mutations in the viral genome 28 . Using LbuCas13a also circumvents reverse transcription, needed for both DETECTR and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 6, 2022. Impairment of the immune system due to infection with SARS-CoV-2 will, in some cases lead to bacterial co-or superinfection, which is often treated with empiric antibiotic therapy, as a preventive strategy [33] [34] [35] . The success of the antibiotherapy, however, strongly depends on keeping the blood antibiotic concentrations within the "personalized" therapeutic range to minimize the risk of antibiotic resistance. Therefore, it is necessary to understand how the patient's body metabolizes the drug with respect to the individual pharmacokinetic (PK) response 36 , i.e., to monitor antibiotic level fluctuations in the serum of a patient 37 . Here we introduce BiosensorX, a novel, multiplexed single-channel biosensor, onto which we immobilize the CRISPR-powered assay as well as a protein-based antibiotic detection assay (Fig. 1) . We thereby demonstrate the versatility of the biosensor's design and provide a multitude of options and combinations of diagnostics, with respect to biomolecules of interest. We were able to conduct screening, confirmatory and discriminatory tests for SARS-CoV-2, as well as a control assay, simultaneously for two clinical specimens. Finally, we tested the credit-card format NFC potentiostat and microperistaltic pump as a compact measurement setup, further improving the pointof-care applicability of our system. BiosensorX is capable of harboring both, the CRISPR-powered assays for the detection of multiple . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint COVID-19-specific RNA sequences and a protein-based assay for ß-lactam monitoring. On-site patient monitoring could, hence, be performed by measuring antibiotic concentrations for personalized drug adjustment and screening for the abundance of the viral RdRP gene, to determine the end of isolation.

For the simultaneous detection of multiple RNA sequences, we modified our existing bioassay 22 to achieve lower detection limits as well as faster turnaround times: i) streptavidin-preincubation was substituted with neutravidin for its superiority in biotin-binding affinity (SI Fig. 1a) , ii) bovine serum albumin, previously used to prevent unspecific binding of biomolecules to neutravidin was substituted with casein: the smaller molecule is able to achieve satisfactory blocking in 30 minutes instead of 1 hour and reduces steric hindrance within the microfluidic channel, facilitating access for the reRNA's biotin label to the binding sites of neutravidin (SI Fig. 1b) . Interestingly, when evaluated for neutravidin-biotin binding specificity the model assay failed to meet our requirements: in the absence of reRNA we were still able to observe a substantial, unspecifically generated amperometric signal (SI Further optimization of the assay, predominantly with respect to its limit of detection (LOD), but also concerning the variability of the individual measurements, was achieved by combining and switching combinations of two different Cas13a effectors (Leptotrichia wadeii (LwCas13a) and Leptotrichia buccalis (LbuCas13a)) with either a 14 nt-long reRNA (random sequence) or a reRNA consisting only of 20 uracil repeats (reRNA_20U) 38 (Fig. 2b-d) . We observed the bioassay's strongest performance when combining LbuCas13a with reRNA_20U. This was apparent in the sharp drop in the amperometric signal measured for 1 pM of target RNA (from undetectable levels to 104.19 µA cm -2 ; 30.4% of the blank signal). Consequently, all following experiments were performed using LbuCas13a as effector and reRNA_20U as the reporter of choice.

Since RNAs are susceptible to degradation by omnipresent RNases, detection systems targeting these oligonucleotides are prone to produce false negative results. In sensitive settings, like nursing homes, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint hospitals or schools this can lead to disastrous results, with regard to the spread of viral material. It is therefore of utmost importance to ensure that each test is working correctly and to rule out contamination with RNases. We, therefore, implemented a positive as well as a negative control, which simultaneously serves as a discriminatory assay to rule out an infection with SARS-CoV-1 31 . The latter constitutes the measurement of a patient sample using a crRNA designed to target the RdRP gene, characteristic to SARS-CoV-1. If this measurement results in a signal of the maximum amplitude, we conclude that (i) the subject is not infected with SARS-CoV-1 and (ii) that none of the reagents are RNase contaminated. The positive control speaks to the general performance of the bioassay: in this case it employs a crRNA designed to target synthetic microRNA-520f (miR-520f, associated with proliferation of lung and gastric cancer cells 39, 40 ), which is added at a concentration high enough to completely eliminate the amperometric signal. These oligonucleotides could, however, be replaced by any other experimentally validated crRNA-target-pair, with a known amperometric readout that can be correlated to the utilized concentrations. To validate our negative and positive control oligonucleotide pairs we conducted measurements for 10 nM, 10 pM, 10 fM as well as a blank measurement (no-target) of the SARS-CoV-1 RdRP gene (Fig. 2e ) and miR-520f (Fig. 2f) .

To rule out the risk of false positive results produced by cross reactivity between crRNAs and nontarget RNA, we measured the blank signals for each crRNA and compared them to the signal measured, when each of the three crRNAs (E, RdRP and SARS-CoV-1 RdRP, which, for ease of legibility, will further be referred to as C-) was incubated with both of the target RNAs (total concentration 100 pM, which would correspond to unrealistically high (~500 million copies/µl) viral loads) for the other two crRNAs From this we conclude the target specificity of our crRNAs and thereby of the bioassay.

In order to determine the statistical LOD of the biosensor, we performed measurements for different concentrations of the synthetic viral E and RdRP genes. Isothermal incubation (37 °C) of the sample solution for 5 minutes already provided results that were clearly distinguishable from the blank signal with the sensor reaching its LOD at 4.06 fM for the E and at 15.04 fM for the RdRP gene ( Fig. 2h-i) .

These target concentrations roughly correspond to 2,000 copies/µl (E) and 7,500 copies/µl (RdRP), and thereby supersede the LODs necessary to detect viral RNA in nasopharyngeal swabs (10 6 -10 9 RNAs /swab) 41 without target amplification. Calibrations measured on actual patient samples will, however, always fall short of the ones performed with synthetic RNA 42 . One solution proposed by Fozouni and colleagues, is a combination of crRNAs: Increasing the number of activated Cas13-effectors and . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint thereby enhancing sensitivity while also providing a safeguard against mutational escape of the virus from detection 43 . We could verify this by combining crRNA(E) with crRNA(RdRP) to record an additional calibration curve, using the synthetic sequences as targets. The analytical LOD of this approach reached 2.6 zM (Fig. 2j) . Another way of circumventing the diminished LOD, obtained when measuring actual samples instead of synthetic targets, is prolonging the reRNA-cleavage time. After even a slight increase from 5 to 10 minutes, we were able to observe a decreased signal amplitude from 66.05% to 42.36% of the blank signal for a target concentration of 100 fM (50,000 copies/µl). Accordingly, after an incubation period of 2 hours, the amperometric signal had decreased to 3.08 % of the blank signal (SI Fig. 4) .

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint

diagnostics. a) Schematic of the CRISPR-Cas13a-powered assay. LbuCas13a (beige: inactive; red: active) and crRNA form a complex within the sample solution, which also contains the target RNA (yellow) and reRNAs (labelled with a biotin (grey) and a 6-FAM molecule (green) on the 3' and 5'-end, respectively). Upon activation by target recognition, the effector collaterally trans-cleaves the reRNA.

The sample solution is then applied to the microchannel, which has been pre-functionalized with neutravidin (mint) and subsequently blocked with casein (dark green) to prevent unspecific binding of 

In an attempt to provide a single platform that can perform both measurement of antibiotic concentration and detection of viral RNA in clinical samples, we combined two different assays on a 6fold BiosensorX (Fig. 3a) : (i) a protein-based assay for ß-lactam monitoring 37 and (ii) a CRISPR/Cas13a powered assay for RNA sequences characteristic to an infection with COVID-19 (Fig. 3b) . To mimic the drug clearance behavior, the first two immobilization areas of BiosensorX were used to perform antibiotic measurements for simulated dosages of piperacillin/tazobactam along with a negative control (blank signal: no antibiotic present in the sample). The three measurement time points represented the start (t = 0, no antibiotic treatment yet), the initial phase (t = 5 min, high levels of antibiotic) and the clearance (4 hours after the initial dose) of the drug within treatment (Fig. 3c-f ).

When the drug concentration was measured 5 minutes after administration, we could observe a sudden drop in the measured signal, indicating a sharp increase in the ß-lactam level. At t = 240 min, . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint the drug concentration is assumed to decrease towards the control level, which we were also successfully able to measure on the multiplexed sensor. Measurement of the viral load (indicated by the respective abundance of E and RdRP copies) is not expected to change within the observed timeframe and is therefore simulated to stay at the initially (t = 0) measured 1 pM (~500,000 copies/µl) within this experiment. The negative control for the CRISPR-based assay in this case was performed with 5 µl of RNase free PBS (10 mM). The positive control successfully detected 1 nM of spiked-in miR-19b, a biomarker for pediatric medulloblastoma, validated in a previous study from our group 22 . These results indicate that the proposed multiplexed biosensor is capable of harboring multiple different bioassays from various biomolecule classes without cross-contamination.

To test the applicability of our multiplexed platform for SARS-CoV-2 detection, we analyzed nasopharyngeal swab samples of two COVID-19 patients with high viral loads (Ct 19 and 17.8, respectively) as well as one specimen taken from a healthy subject. We employed the 4-fold BiosensorX to conduct the positive control (in this case miR-520f; 100 pM), and discriminatory (RdRP SARS-CoV-1) assay, as well as the screening (E) and confirmatory assay (RdRP SARS-CoV-2) simultaneously ( Fig. 3g-i) . Each sample was measured on two individual multiplexed biosensors and the signals obtained from the infected individuals for the E and RdRP genes were normalized to their counterparts measured for the healthy subject. We were able to obtain consistent values for C+ . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. 

Over two years of the still ongoing COVID-19 pandemic has lead researchers to the consensus that the frequency and sample-to-result time of tests should be prioritized over an LOD that can compete with that of RT-qPCR (LOD: 10-100 copies/µl, full range of viral titers between Ct 17-38 and turnaround times of 24-48 hours) 15, 32, 44, 45 . Peak viremia has been reported at the time of symptom onset with . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint infectiousness declining until day eight to ten after which the probability of transmission is almost none. In some cases, positive PCR-results can be obtained until as much as 50 days after onset, at which point the patient is very unlikely to still be infectious 41, 46, 47 . Generally, an individual is considered infectious if both the antigen as well as the PCR tests show positive results, whereas viral loads below 10 3 copies/µl are associated with a low risk of infectiousness 41, 48 .

While RT-qPCR is still considered the gold standard for the detection of nucleic acids, quantitatively comparing different Ct levels across laboratories is difficult (some studies describe Ct values <30 as The most common form of COVID-19 diagnostic to date is the rapid antigen test on a lateral flow device (LFD). Due to their easy handling, short sample-to-result time and straightforward readout, test kits employing LFDs have been established for at-home testing, as well as for state-certified tests (Germany), with sensitivities between 70-80% (>90% sensitivity for patients with Ct<25) and specificities ≥99.7% 55, 56 . Results are usually provided within 30 minutes, but also require high viral loads to turn out positive 57 , which begs the question: Are people tested negative with an LFD today going to be infectious tomorrow? I.e., have they been exposed to the virus but have not yet amplified the virus particles to supersede the LOD of the test?

An approach to circumvent this issue is the utilization of CRISPR/Cas systems, which, even without amplification strategies are able to reach LODs below 50 fM (~30,000 copies/µl) 58 is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint proposed by Fozouni and colleagues, is the combination of multiple target-complementary sequences into a single crRNA (~200 copies/µl in under 30 min) 65 .

In this study, we combine a multiplexed CRISPR-based detection system with an electrochemical readout to target unamplified oligonucleotide sequences characteristic for SARS-CoV-2: one within the envelope (E) and another from the RNA-dependent RNA Polymerase (RdRP) gene 31 , with the primerprobe set for the former being validated by Vogels and colleagues 32 . The former non-specifically indicates infection with a member of the Betacoronavirus genus 66 , the latter is specific to SARS-CoV-2 31 . Like Corman and colleagues we also implement a discrimination assay to rule-out infection with the 2003 SARS-CoV, using a characteristic target within the SARS-CoV-1 RdRP gene. While this method requires slightly more expertise than the optical readout of a conventional LFD, it only produces a fraction of the waste. In addition, the substrate, glucose, is stable over long periods of time, inexpensive and non-toxic. Within a sample-to-result time of about 30 min we were able to obtain an LOD of 2,000 copies/µl for the E gene, 7,520 copies/µl for RdRP and <1 copy/µl for a combination of the targets. However, since all calibrations were measured using synthetic target-oligonucleotides, the LODs cannot be translated directly to clinical specimen, which are likely to be much higher, due to a multitude of different RNAs, other than only the reporter. An indication therefore are the proof-ofprinciple measurements that we conducted on the clinical samples of two COVID-19 patients with high viral loads. We could, however, measure distinctly reduced amperometric signals for the RdRP gene in these samples, whereas interpretation of the results for the E gene was difficult. Because of the discrepancy in their respective LODs (E: 4.06 fM; RdRP: 15.04 fM) and also because E (as well as Orf7 and the nucleocapsid gene) is highly abundant in subgenomic RNA, which often leads to a 100-1,000fold overestimation of a patient's viral load 51 the E gene signals were assumed to fall below the ones measured for RdRP, which they did not. One possible explanation for these results is a mutation within the E gene sequence of the viral genome that occurred at some point since the establishment of the Corman protocol in 2020, leading to partial failure of recognition by the crRNA, that was designed according to a protocol from 2020 31 .

Despite the relatively short turnaround time, adequate LOD and reasonable pricing (3 € for the entire COVID-19 diagnostics on a 4-fold biosensor; see Supplementary Table S3) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint development of specified treatment plans. Studies have also shown that the Cas13a-crRNA complex is stable 58 and can be lyophilized and rehydrated for use at the POC, which would improve its applicability in remote locations to which continuously refrigerated transport is difficult. In addition, our experimental results could also benefit from optimization of the upstream sample processing. While we avoid the risk of skewing our analysis by unbalanced amplification of RNAs, sample preparation is still a factor that can have major impacts on the experimental outcome. Choice of the lysis buffers, for example, can yield vastly variable results, depending on its components 42 73 other studies claim the sample processing step to be unnecessary 12, 74, 75 . Furthermore, as there are still 5 steps that require user interventions, our protocol is prone to RNase contaminations and errors due to misuse. Reducing these steps to ideally only three hands-on steps, (addition of the sample to the mastermix, application of the mastermix to the microfluidic device and readout) requires further studies. These are, however, warranted, since, due to constantly evolving new variants, but also waning of the neutralizing antibody response 76,77 the need for rapid and frequent testing for SARS-CoV-2 will likely remain.

The platform introduced in this study presents a direct approach to quantifying the viral load of a clinical sample in approximately 30 min with the potential for combination with a variety of assays from other biomolecule classes. In this case, we chose protein-based monitoring of antibiotic levels, since bacterial co-or superinfections often coincide with viral primary infections and are preventatively treated with generic antibiotics. The obtained amperometric signal directly correlates to viral copy numbers and may be used for quantification of viral loads across laboratories, without the need for extensive system calibrations. Since we use a syringe pump, an in-house designed chip-holder with attached printed circuit board and a potentiostat, our method is suited for testing facilities, e.g., in retirement homes, schools, or prisons where it could be used for rapid and frequent screening for infectious individuals. Additionally, we were able to miniaturize the on-site measurement setup by using a microperistaltic pump and a credit card-sized NFC potentiostat (Fig. S13) to improve the cost effectiveness and ease of setup. In conclusion, frequency of screening is understandably favored in the trade-off with accuracy, it is advisable to work with all three: high frequency, low LOD and short sample-to-result / waiting times, as well as to educate about the risks and benefits of vaccinations to limit misinformation and to contain the spread of SARS-CoV-2.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint of the pure protein is determined by analyzing the SDS gels with ImageJ. Aliquots are stored at -80 °C and freshly thawed for each experiment.

All tests are performed on pre-incubated microfluidic biosensor chips: the immobilization areas are first incubated with neutravidin (0.8 mg ml -1 in PBS (10 mM; pH 7.4); 31000; ThermoFisher Scientific, USA) for one hour, followed by a 30-minute incubation with casein (85R-108; Fitzgerald, USA), both at 25 °C. These steps provide high affinity binding sites for the biotin label on the reporter RNA (reRNA_20U) and block unspecific binding of biomolecules to the surface of the microfluidic channel. 

Functionalization of the immobilization area is accomplished by incubation with penicillin binding protein 3 (PBP-3 37 ; 250 µg ml -1 in PBS (10 mM; pH 7.4), expressed via in-house production) for 1 hour, followed by 30 minutes of blocking with biotin-free casein (85R-108, Fitzgerald, USA). The third step of the assay relies on the competitive binding of piperacillin-tazobactam and/or biotinylated ampicillin (0.2 µg ml -1 in PBS (10 mM; pH 7.4) obtained via in-house production) to PBP-3. At the last step, the channel surface is incubated with avidin-GOx (50 µg ml -1 (A4500-70.2, Biomol, Germany) in PBS (10 mM; pH 7.4) for 15 minutes.

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

COVID-19: Knowns, Unknowns, and Questions

Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship

Estimation of the asymptomatic ratio of novel coronavirus infections (COVID-19)

Clinical and immunological assessment of asymptomatic SARS-CoV-2

Coronavirus Disease 2019-COVID-19

Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV

SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay

Rapid coronavirus tests: a guide for the perplexed

RT-PCR for SARS-CoV-2: quantitative versus qualitative

Rethinking Covid-19 Test Sensitivity -A Strategy for Containment

CRISPR -Cas12-based detection of SARS-CoV-2

Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens

Ultra-Low-Cost Integrated Silicon-based Transducer for On-Site , Genetic Detection of Pathogens

CRISPR-Cas immunity in prokaryotes

Multiplex Genome Engineering Using CRISPR-Cas Systems. Science (80-. )

A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science (80-. )

CRISPR/Cas13a-Powered Electrochemical Microfluidic Biosensor for Nucleic Acid Amplification-Free miRNA Diagnostics

CRISPR-Cas12a has both cis-and trans-cleavage activities on single-stranded DNA

Evolutionary classification of CRISPR-Cas systems: a burst of class 2 and 26

Duplex-Specific Nuclease-Assisted CRISPR-Cas12a Strategy for MicroRNA Detection Using a Personal Glucose Meter

RNA targeting with CRISPR-Cas13

Development of CRISPR as an Antiviral Strategy to Combat SARS-CoV-2 and Influenza

Rapid Detection of 2019 Novel Coronavirus SARS-CoV-2 Using a CRISPRbased DETECTR Lateral Flow Assay

SHERLOCK: nucleic acid detection with CRISPR nucleases

Diagnostic detection of 2019-nCoV by real-time RT-RCR incl

Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets

Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19?

Increased antimicrobial resistance during the COVID-19 pandemic

Personalized ß-lactam dosing in patients with coronavirus disease 2019 (COVID-19) and pneumonia: A retrospective analysis on pharmacokinetics and pharmacokinetic target attainment

On-Site Therapeutic Drug Monitoring

Biosensor-Enabled Multiplexed On-Site Therapeutic Drug Monitoring of Antibiotics

Kinetic analysis of Cas12a and Cas13a RNA-Guided nucleases for development of improved CRISPR-Based diagnostics

MiR-520f acts as a biomarker for the diagnosis of lung cancer

MicroRNA-520f-3p inhibits proliferation of gastric cancer cells via targeting SOX9 and thereby inactivating Wnt signaling

Virological assessment of hospitalized patients with COVID-2019

ADESSO detects SARS-CoV-2 and its variants: ex tensive clinical validation of an optimised CRISPR-Cas13-based COVID-19 tes

Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy

Test sensitivity is secondary to frequency and turnaround time for COVID-19 screening

Analytical sensitivity and efficiency comparisons of SARS-COV-2 qRT-PCR assays

Temporal dynamics in viral shedding and transmissibility of COVID-19

Diagnostics for SARS-CoV-2 infections

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1. medRxiv 1-13

Predicting infectious SARS-CoV-2 from diagnostic samples

Viral RNA load as determined by cell culture as a management tool for discharge of SARS-CoV-2 patients from infectious disease wards

SARS-CoV-2 genomic and subgenomic RNAs in diagnostic samples are not an indicator of active replication

It's Like Having No Testing': Coronavirus Test Results Are Still Delayed -The New York Times

the State of the Nation: a 50-State Covid-19 Survey Report #18: Covid-19 Fake News on Twitter

COVID-19: Rapid Antigen detection for SARS-CoV-2 by lateral flow assay: a national systematic evaluation for mass-testing

Validation testing to determine the effectiveness of lateral flow testing for asymptomatic SARS-CoV-2 detection in low prevalence settings

Fast Coronavirus Tests Are Coming

Nucleic acid detection with CRISPR-Cas13a/C2c2. Science (80-. )

RNA Targeting by Functionally Orthogonal Type VI-A CRISPR-Cas Enzymes

The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a

Equipment-free detection of SARS-CoV-2 and Variants of Concern using Cas13

A protocol for detection of COVID-19 using CRISPR diagnostics

Rapid Detection of SARS-CoV-2 by Low Volume Real-Time Single Tube Reverse Transcription Recombinase Polymerase Amplification Using an Exo Probe with an Internally Linked Quencher (Exo-IQ)

Detection of SARS-CoV-2 and Its Mutated Variants via CRISPR-Cas13-Based Transcription Amplification

Direct detection of SARS-CoV-2 using CRISPR-Cas13a and a mobile phone

Coronavirus genomics and bioinformatics analysis. Viruses

Antibody Responses to SARS-CoV-2 in Patients with Novel Coronavirus Disease

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Simultaneous detection of SARS-CoV-2 RNA and host antibodies enabled by a multiplexed electrochemical sensor platform Helena

The Prediction of miRNAs in SARS-CoV-2 Genomes: hsa-miR Databases Identify 7 Key miRs Linked to Host Responses and Virus Pathogenicity-Related KEGG Pathways Significant for Comorbidities

Multiplexed CRISPR-based microfluidic platform for clinical testing of respiratory viruses and identification of SARS-CoV-2 variants

Field-deployable viral diagnostics using CRISPR-Cas13. Science

A 5-min RNA preparation method for COVID-19 detection with

Optimization of SARS-CoV-2 detection by RT-QPCR without RNA extraction

Rapid SARS-CoV-2 testing in primary material based on a novel multiplex LAMP assay

The dynamics of humoral immune responses following SARS-CoV-2 infection and the potential for reinfection

Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Dry film photoresist-based electrochemical microfluidic biosensor platform: Device fabrication, on-chip assay preparation, and system operation

Designed miniaturization of microfluidic biosensor platforms using the stopflow technique

Similar to the single-analyte version, the multiplexed electrochemical biosensor consists of either four (0.61 µl) or six (0.67 µl) functionalized zones (length: 19 mm, surface area: 12.27 cm 2 for the four-channel and length: 19 mm, surface area: 12.93 cm 2 for the six-channel version), each complete with their own inlets, outlets and electrochemical cells. With this design, it is possible to functionalize each immobilization area separately which enables a combination of different assays on the same chip. While the electrochemical cells of single and 4-analyte designs have their own counter, reference and working electrode

Bacteria are grown in LB medium (Carl Roth, Germany) containing 100 µg mL -1 ampicillin (Roth) and 36 µg ml -1 chloramphenicol (Carl Roth, Germany) at 37 °C, 150 rpm. Once OD600 = 0.6 is reached, protein production is induced with 1 mM isopropyl ß-D-1-thiogalactopyranoside (IPTG) (Carl Roth, Germany) for 16 h at 16 °C. Cells are harvested by centrifugation at 6,000 × g for 10 min and the bacterial pellets are resuspended in Ni-lysis buffer (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 8.0) and lysed using a French press

Cellular debris is removed by centrifugation at 30,000 × g for 30 min at 4 °C and the supernatant is purified by gravity flow Ni 2+ -NTA chromatography using superflow agarose (Qiagen GmbH, Germany) following the manufacturer's instructions and the eluate is supplemented with 1 mM

The authors would like to thank the Deutsche Forschungsgemeinschaft (DFG, German Research 

. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03. 30.22271928 doi: medRxiv preprint Unbound biomolecules are flushed (PBS (10 mM) with 0.05% Tween, pH 7.4, P3563, Merck, Germany) after each incubation step for an accurate amperometric readout. Changing the incubation solutions as well as rinsing of the microchannel are performed by application of a vacuum to the outlet of the microchannel in order to avoid contamination of the electrochemical cell.

Once the immobilization of the assay has been completed the biosensor is placed into a custom-made chip-holder on a printed circuit board (Beta LAYOUT GmbH, Germany), connecting to a four-channel potentiostat (MultiEmStat3 for single and 4-analyte biosensor, EmStatMux8 for 6-analyte biosensor; 

Lysis Solution (09N20-001, Abbott, USA). Subsequently, the RNA extraction was performed using

RNAse-free environment. It needs to be noted, that due to very small volumes of isolated RNA the discriminatory assay for patient 2 was conducted with PBS instead of actual clinical sample.. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint

To perform the amperometric signal readout, the microfluidic biosensor needs to be electrically and fluidically integrated into the measurement setup via a custom-made chip holder 78 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted April 6, 2022. ; https://doi.org/10.1101/2022.03.30.22271928 doi: medRxiv preprint